Vasopressin antagonists for the treatment of acute decompensated heart failure: when, for whom, for how long, and on what standard therapy?

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Journal of Cardiac Failure

• Publication date

  2008-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.cardfail.2008.08.003PMID 18926435
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• VASOPRESSIN STIMULATES THE PRODUCTION OF EXTRACELLULAR MATRIX BY CULTURED RAT MESANGIAL CELLS

  2008cited by this paper
• Non-peptide arginine-vasopressin antagonists: the vaptans.

  2008cited by this paper
• Overview of emerging pharmacologic agents for acute heart failure syndromes

  2008cited by this paper
• Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study.

  2008cited by this paper
• Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study.

  2007cited by this paper
• Aquaretic agents: what's beyond the treatment of hyponatremia?

  2007cited by this paper
• Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction.

  2007cited by this paper
• An introduction to acute heart failure syndromes: definition and classification

  2007cited by this paper
• Epidemiology of acute heart failure syndromes

  2007cited by this paper
• Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.

  2007cited by this paper
• Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial

  2007cited by this paper
• Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.

  2007cited by this paper
• Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients.

  2006cited by this paper
• Congestion in acute heart failure syndromes: an essential target of evaluation and treatment.

  2006cited by this paper
• Acute Heart Failure Syndromes: Current State and Framework for Future Research

  2005cited by this paper
• Vasopressin antagonism in heart failure.

  2005cited by this paper
• Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure.

  2005cited by this paper
• Effects of Tolvaptan, a Vasopressin Antagonist, in Patients Hospitalized with Worsening Heart Failure: A Randomized Controlled Trial

  2004cited by this paper
• Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.

  2004cited by this paper
• ACUTE AND CHRONIC THERAPEUTIC IMPACT OF A VASOPRESSIN ANTAGONIST IN CONGESTIVE HEART FAILURE (ACTIV IN CHF) INVESTIGATORS. EFFECTS OF TOLVAPTAN, A VASOPRESSIN ANTAGONIST, IN PATIENTS HOSPITALIZED WITH WORSENING HEART FAILURE: A RANDOMIZED CONTROLLED TRIAL

  2004cited by this paper
• Vasopressin: a new target for the treatment of heart failure.

  2003cited by this paper
• Vasopressin V2-Receptor Blockade With Tolvaptan in Patients With Chronic Heart Failure: Results From a Double-Blind, Randomized Trial

  2003cited by this paper
• Acute Hemodynamic Effects of Conivaptan, a Dual V1A and V2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure

  2001cited by this paper
• Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure.

  2001cited by this paper
• Selective vasopressin, angiotensin II, or dual receptor blockade with developing congestive heart failure.

  2000cited by this paper
• Vasopressin: a therapeutic target in congestive heart failure?

  1999cited by this paper

• Cardiorenal syndrome in patients with heart failure as a stage of the cardiorenal continuum (part 2): prognosis, prevention and treatment

  2019cites this paper
• Кардиоренальный синдром у больных с сердечной недостаточностью как этап кардиоренального континуума (часть 2): прогностическое значение, профилактика и лечение

  2019cites this paper
• Can we prevent or treat renal dysfunction in acute heart failure?

  2012cites this paper
• Can we improve the treatment of congestion in heart failure?

  2011cites this paper
• Eski Hastaliklar İçin Yeni Firsatlar: Akuaretikler (Vazopresin Reseptör Antagonistleri) New Options for Old Diseases: Aquaretics (Vasopressin Receptor Antagonists)

  2011cites this paper
• Acute Heart Failure Syndromes: The Role of Vasopressin Antagonists

  2009cites this paper
• Current drugs and medical treatment algorithms in the management of acute decompensated heart failure

  2009cites this paper
• Current drugs and medical treatment algorithms in the management of acute decompensated heart failure.

  2009cites this paper